Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Cretostimogene Grenadenorepvec in people with high-risk non-muscle-invasive bladder cancer NMIBC. This Phase 2, multi-arm, open-label study includes participants who are either new to Bacillus Calmette-Guerin BCG treatment, previously treated with BCG, or unresponsive to BCG. The study aims to compare different administration methods and combinations with gemcitabine to better understand treatment options for this condition. Participants are divided into several groups based on their disease status and prior BCG treatment. The study drug Cretostimogene is administered directly into the bladder weekly for six weeks as an induction course, followed by reinduction for certain participants. Maintenance treatment involves cycles of three weekly doses every three months in the first year and every six months in the second year, with an optional extension to the third year. Some groups receive Cretostimogene alone, while others receive it combined with gemcitabine through alternative instillation methods. Participants will have their disease status monitored through urine tests, bladder visualizations like cystoscopy, upper urinary tract assessments, and biopsies if needed every three months for two years, then every six months for up to an additional two years or until disease recurrence. The study measures include complete response rates, event-free survival, and safety outcomes over periods ranging from weeks to 48 months. Overall participation may last several years, with careful follow-up to assess treatment impact and safety.
Actively Recruiting
This research aims to evaluate the clinical outcomes of the Axonics Sacral Neuromodulation SNM System in treating overactive bladder OAB in male patients. It focuses on men who have previously undergone radical prostatectomy, radiation therapy for prostate cancer, or cytoreductive surgery for benign prostatic hyperplasia BPH. The study is an interventional, non-randomized trial sponsored by Axonics, Inc., assessing safety and effectiveness in this specific population. Participants will receive the Axonics SNM System, a device designed to manage symptoms of OAB such as urinary urgency incontinence and urinary frequency. The trial includes groups based on prior treatments post-prostatectomy, radiation, or BPH surgery, with at least six months since those interventions. The study tracks participants for up to one year after treatment to monitor outcomes. During the study, participants will complete bladder diaries and questionnaires to report symptoms and quality of life. Researchers will monitor adverse events and measure reductions in urinary urgency incontinence and frequency at 6 months and 1 year. Quality of life improvements will also be assessed. Participants must attend follow-up assessments throughout the year to support thorough evaluation of device performance and safety.